– ISRAEL, Petach Tikva – Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that at its Annual General Meeting of Shareholders held earlier today, Shareholders voted to approve the elections of Murray Goldberg, Roberto Mignone, Dr. Perry Nisen and Nechemia (Chemi) Peres to the Company’s Board of Directors.
“We greatly appreciate the support of Teva’s shareholders as we work to strengthen the leadership of Teva, with the addition of these distinguished Board members, and our ongoing search to find the best chief executive officer to lead Teva,” stated Dr. Sol Barer, Chairman of the Board. “We continue to make changes to enhance our Board of Directors; address matters that are important to our shareholders, and continue to look for opportunities to make a difference to patients and healthcare systems around the world.”
Dr. Barer continued, “We are pleased to have added these world class directors to our Board from both Israel and around the world. Teva has become a global company by putting innovation front and center and never shying away from change. Teva’s new directors share our conviction that innovation is at the heart of Teva’s strategy and of all our businesses – a conviction with clear roots in Israel. The primary task for our new leadership, which will include a new CEO, will be to best position Teva to handle today’s challenges and prepare the Company for the emerging pharma landscape. I would like to take this opportunity to thank our outgoing directors, Ory Slonim and Roger Abravanel, who are leaving us today, and Yossi Nitzani, who is leaving in September, for their wisdom and dedication to Teva.”
Four New Independent Directors Join the Teva Board
Murray Goldberg, the former Chief Financial Officer and Senior Vice President of Administration of Regeneron Pharmaceuticals, who brings extensive financial and operational experience at leading global pharmaceutical companies.
Roberto Mignone, the founder and managing partner of Bridger Management LLC, where he oversees the management of approximately $1 billion invested in publicly traded healthcare companies.
Dr. Perry Nisen, who brings two decades of experience in a variety of senior roles in pharmaceutical research and development at non-profits and global pharmaceutical companies like GlaxoSmithKline and Abbott Laboratories and is currently the Chief Executive Officer and Chief Executive Chair of Sanford Burnham Prebys Medical Discovery Institute.
Chemi Peres, the managing general partner and co-founder of Pitango Venture Capital, who oversees a diverse investment portfolio spanning health care to IT.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva’s net revenues in 2016 were $21.9 billion.
For more information : http://www.tevapharm.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.